This Count the Costs briefing explores how the UN seeks to promote the security of its member states through implementing a drug control system that treats the use of certain drugs as an ‘existential threat’ to society.
The objectives of these updated WHO Guidelines are to provide evidence-based recommendations for the treatment of persons with hepatitis C infection using, where possible, all-oral combinations of these new medicines, also called direct-acting antivirals (DAAs).
Amnesty International focuses on the issue of the death penalty for drug-related offences, as well its implications particularly for foreign nationals sentenced abroad.
This briefing highlights the impact on the lives of people who inject drugs (PWID) and their family members of the Community Action on Harm Reduction (CAHR) programme.
The LSE Expert Group on the Economics of Drug Policy suggests a new set of guiding policy principles for both the national and international levels, based on the Sustainable Development Goals.
From 2014 to 2015 Mainline, together with its local partner Tanadgoma, implemented a series of interventions around Hepatitis C, aiming to understand the gaps and barriers to enrollment in the care cascade of hepatitis C prevention and treatment from the community perspective.
This IDPC advocacy note offers some reflections and recommendations on the negotiation process itself, and some general proposals on the overarching tone that should be reflected in the final document.
